Literature DB >> 2057005

Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients.

I T Lorentz1, S S Subramaniam, C Yiannikas.   

Abstract

In a double-blind, placebo-controlled study, 23 patients suffering from intractable spasmodic torticollis (ST) were given successively either botulinum toxin A (BTA) or normal saline by intramuscular injections in the affected muscles. Evaluation was carried out by three blinded observers, using a clinical and video assessment of the severity of torticollis, employing a scoring system described by Tsui (1). Patients were also asked to subjectively comment on changes in the amount of pain and on changes in the activities of daily living (ADL). BTA was proven to be superior on all forms of assessment to placebo, and these results were statistically significant. Side effects mainly consisted of pain at the injection site. Tiredness occurred at equal frequency with BTA and placebo. No serious or systemic side effects were noted. Botulinum toxin is a safe, effective and relatively simple treatment for spasmodic torticollis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2057005     DOI: 10.1002/mds.870060210

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

Review 1.  The treatment of cervical dystonia with botulinum toxins.

Authors:  C L Comella
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

2.  What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.

Authors:  W Poewe; G Deuschl; A Nebe; E Feifel; J Wissel; R Benecke; K R Kessler; A O Ceballos-Baumann; A Ohly; W Oertel; G Künig
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

3.  Nociceptive pathway function is normal in cervical dystonia: a study using laser-evoked potentials.

Authors:  Michele Tinazzi; Massimiliano Valeriani; Giovanna Squintani; Federica Corrà; Serena Recchia; Giovanni Defazio; Alfredo Berardelli
Journal:  J Neurol       Date:  2012-02-18       Impact factor: 4.849

Review 4.  Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin.

Authors:  Maria Fiorella Contarino; Joost Van Den Dool; Yacov Balash; Kailash Bhatia; Nir Giladi; Johannes H Koelman; Annemette Lokkegaard; Maria J Marti; Miranda Postma; Maja Relja; Matej Skorvanek; Johannes D Speelman; Evelien Zoons; Joaquim J Ferreira; Marie Vidailhet; Alberto Albanese; Marina A J Tijssen
Journal:  Front Neurol       Date:  2017-02-24       Impact factor: 4.003

5.  Botulinum toxin: dangerous terminology errors.

Authors:  M F Brin; A Blitzer
Journal:  J R Soc Med       Date:  1993-08       Impact factor: 5.344

Review 6.  Botulinum toxin type A therapy for cervical dystonia.

Authors:  Mafalda Castelão; Raquel E Marques; Gonçalo S Duarte; Filipe B Rodrigues; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2017-12-12

Review 7.  Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology.

Authors:  A Berardelli; G Abbruzzese; L Bertolasi; G Cantarella; F Carella; A Currà; D De Grandis; G DeFazio; G Galardi; P Girlanda; P Livrea; N Modugno; A Priori; G Ruoppolo; L Vacca; M Manfredi
Journal:  Ital J Neurol Sci       Date:  1997-10

8.  Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.

Authors:  G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

Review 9.  Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.

Authors:  Wilhelm J Schulte-Mattler
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance.

Authors:  J W Brans; I P de Boer; M Aramideh; B W Ongerboer de Visser; J D Speelman
Journal:  J Neurol       Date:  1995-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.